Jazz Trumpets 2025 Strategy With Neurology, Oncology Focus
The company laid out plans at J.P. Morgan to reach revenues of $5bn by 2025, focusing on already marketed products and its pipeline plans.
You may also be interested in...
Deal Snapshot: The two companies will collaborate on drugs targeting two ion channels in neurological disorders, with Autifony receiving upfront and milestone payments up to $770.5m.
The deal focuses on the HER2-targeting bispecific antibody zanidatamab, in development for multiple solid tumor indications expressing HER2.
The Irish firm’s cannabis-derived nabiximols spray missed the primary endpoint in a late-stage multiple sclerosis spasticity trial, but it is unfazed as hopes remain for two ongoing spasticity studies.